Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Gusperimus. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 2/20 | 0.43 |
| ▸ | CHRNA3 known ✓ | P32297 | 2/20 | 0.43 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 8/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gusperimus SCHEMBL7320030 | 1.00 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Gusperimus SCHEMBL12980163 | 1.00 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL9772175 | 1.00 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL9772231 | 1.00 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL9772186 | 1.00 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Gusperimus SCHEMBL317912 | 1.00 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Gusperimus SCHEMBL317327 | 1.00 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Gusperimus SCHEMBL10910437 | 0.99 | GRIA1 (0.45) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9772173 | 0.99 | GRIA1 (0.47) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL9772154 | 0.99 | GRIA1 (0.44) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10058641-B2 | Medical devices containing rapamycin analogs | ABBOTT LABORATORIES (US) | 2018-08-28 | — | — | US | disclosed |
| EP-3175870-A1 | MEDICAL DEVICE HAVING HYDRATION INHIBITOR | Abbott Laboratories (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-3138531-A1 | COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS USING MEDICAL DEVICES FOR LONG-TERM EFFICACY | Abbott Laboratories (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2358299-B1 | BODY LUMEN FILTER RETRIEVAL SYSTEM AND METHODS FOR FILTERING A BODY LUMEN | ABBOTT LABORATORIES VASCULAR ENTPR LTD (IE) | 2017-02-15 | — | — | EP | disclosed |
| US-9504551-B2 | Apparatus for filtering a body lumen | ABBOTT LABORATORIES VASCULAR ENTERPRISES LIMITED (IE) | 2016-11-29 | — | — | US | disclosed |
| EP-2387373-B1 | METHODS AND APPARATUS FOR FILTERING A BODY LUMEN | ABBOTT LAB VASCULAR ENTPR LTD (IE) | 2016-10-12 | — | — | EP | disclosed |
| EP-1427457-B1 | MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS | ABBOTT LAB (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160220739-A1 | MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS | ABBOTT LAB (US) | 2016-08-04 | — | — | US | disclosed |
| US-9375304-B2 | Methods and apparatus for filtering a body lumen | ABBOTT LABORATORIES VASCULAR ENTERPRISES LIMITED (IE) | 2016-06-28 | — | — | US | disclosed |
| EP-2493419-B1 | Medical device for treatment of a lumen | ABBOTT LAB VASCULAR ENTPR LTD (IE) | 2016-05-04 | — | — | EP | disclosed |
| WO-1999020267-A1 | FURANYL, TETRACYCLIC TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999015530-A1 | TETRAZOLE-CONTAINING RAPAMYCIN ANALOGS WITH SHORTENED HALF-LIVES | ABBOTT LABORATORIES (US) | 1999-04-01 | — | — | WO | disclosed |
| EP-0858456-A4 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0858456-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | disclosed |
| EP-0858332-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998016518-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016531-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998016532-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1998-04-23 | — | — | WO | disclosed |
| WO-1997016182-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997016437-A1 | TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10058641-B2 | Medical devices containing rapamycin analogs | PGF, RICTOR, MMP9 | CHRNB4 4873/4885CHRNA3 4869/4885GRIN1 4190/4885 |
| US-20160220739-A1 | MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS | PGF, RICTOR, MMP9 | CHRNB4 4873/4885CHRNA3 4869/4885GRIN1 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.